摘要
目的:观察STA-21治疗寻常型银屑病的临床疗效与安全性。方法:分别在13例寻常型银屑病患者双下肢选取临床表现、大小和部位相一致的皮损,分别外用0.2%STA-21软膏和软膏基质治疗2周,记录治疗前后的PASI分值。结果:治疗组有效率为84.61%,对照组为30.77%,差异有统计学意义(x2=4.887,P=0.027)。两组均未无明显不良反应。结论:STA-21治疗寻常型银屑病有较好的疗效与安全性。
Objective： To evaluate the clinical efficacy and safety of STA-21 in the treatment of psoriasis vulgaris.Methods： Thirteen cases of psoriasis vulgaris were recruited for the study,in whom target lesions from different lower limbs,with similar clinical manifestation,size and location,were selected for the 2 weeks＇ treatment of 0.2% STA-21 oinment and the matrix,respectively.The PASI scors of prior-and post-treatment were evaluated.Results： The effective rate was 84.61% in STA-21 group and 30.77% in the matrix group,respectively.There was a statistically significant difference between the 2 groups（chi-square=4.887,P=0.027）.No adverse effects were observed.Conclusion： STA-21 may be optional on the treatment of psoriasis vulgaris with good efficacy and safety.
出处
《现代生物医学进展》
CAS
2013年第16期3099-3101,共3页
Progress in Modern Biomedicine
